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Abstract 
Flortaucipir PET, a marker of tau tangles,  has shown lower than expected cortical uptake in Parkinson’s disease (PD), 
than would be predicted from neuropathologic estimates of Alzheimer’s disease co-pathology. Instead, the most 
characteristic finding of flortaucipir imaging in PD is decreased uptake in the substantia nigra, reflecting reduction in 
its “off-target” binding to neuromelanin. We have previously reported these observations in cross-sectional studies. 
Here, we present data from the same PD subjects after a two-year follow-up. 
Methods 
Seventeen Parkinson’s disease patients received repeat flortaucipir PET two years after baseline. We interrogated  
vertex-based group-wise cortical tracer binding (SUVRs) with a cerebellar reference using the general linear model 
while mean substantia nigra SUVRs were compared with volumes of interest group comparisons and voxel-wise 
group analyses using ANOVA. Finally, we performed linear regressions of tau load with changes in MoCA and UPDRS 
motor scores. 
Results 
We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson’s disease patients over 
two years and no correlations with changes in cognitive symptoms. Signal reduction in the medial substantia nigra 
trended towards a correlation with worsening of motor symptoms.  
Conclusion 
No significant increase in tau tangles occurred after a two-year follow-up of Parkinson’s disease patients using 
flortaucipir PET. 
  
Introduction 
Tau paired helical and linear tangle imaging in Parkinsonian disorders has potential for differential diagnostic use and 
for identifying subgroups of Parkinson’s disease (PD) patients likely to benefit from treatment targeting Alzheimer 
disease (AD) co-pathology. However, initial results from tau imaging studies in PD have shown inconsistent findings. 
Most studies have been conducted with the first generation tau-paired helical tangle tracer flortaucipir, previously 
known as [18F]-T807 and [18F]-AV14511. Other first generation tracers include [18F]-THK5351 and [11C]-PPB32; the 
former has subsequently been shown to preferentially bind MAO-B3 while PPB3 binds to both linear and paired 
helical tau fibrils. 
The differential diagnostic potential of tau imaging within Parkinsonian disorders relies on differences in tangle 
distribution in PD and the tauopathies progressive supranuclear palsy and corticobasal degeneration4. However, in 
vivo flortaucipir binding to the 4-repeat tau present in the atypical diseases has proven to be lower than expected 5,6. 
Analyses have been further complicated by the presence of additional binding targets in key regions of interest, 
including neuromelanin in the substantia nigra5,7, monoamine oxidase type A (MAO-A)8, monoamine oxidase type B 
(MAO-B)8 in areas with gliosis3,9,10, age- and iron-containing targets in the basal ganglia11, and uptake by the choroid 
plexus. 
Tau binding of flortaucipir has also proven lower than predicted  in PD from pathological studies 12–16,17, and is often 
absent even when PD is associated  with single and multi-domain mild cognitive impairment 13,16, in contrast to its 
frequent presence in pre-clinical Alzheimer’s disease18–21. 
The most striking feature in flortaucipir imaging of patients with PD is the loss of signal seen in the substantia 
nigra7,12,14,16. This most likely reflects a loss of neuromelanin, levels of which have been extensively studied using 
post-mortem methods. Neuromelanin shows a continuous buildup with age22, and progressive loss in PD23. In this 
study, we present a two year follow-up findings of flortaucipir binding in the substantia nigra7 and cortex of PD 
patients13. 
Methods 
Recruitment 
Patients with PD were recruited as previously described7,13, and stratified into groups with (PD-MCI) or without (PD-
nonMCI) mild cognitive impairment after baseline neuropsychometric evaluation, as described13. Due to radiation 
dose considerations, we were unable to perform follow-up PET on healthy controls.  
Follow-up 
Follow-up involved repeat interviews, Montreal cognitive assessments (MoCA), ratings with the Unified Parkinson’s 
Disease Rating Scale Part 3 (UPDRS-III) and flortaucipir positron emission tomography (PET) as previously described7. 
In short, subjects were injected with 300 MBq of 18F-flortaucipir. Transmission scans were performed from 74 to 80 
min and emission scans in list-mode from 80 to 120 min post-injection. The PET emission data were binned into eight 
time frames of 5 min each. Image based frame-by-frame motion correction was performed if needed. All follow-up 
scans were performed with the same Siemens High-Resolution Research Tomograph (ECAT HRRT; CTI /Siemens) as 
used for baseline scans. All UPDRS-III ratings were performed in the ON state at both baseline and follow-up. 
PET analysis 
Significant changes in PET uptake data over two years were interrogated with Statistical Parametric Mapping version 
12 (SPM12, http://www.fil.ion.ucl.ac.uk/spm/) on a  MATLAB R2017b (MathWorks, Natick, Massachusetts, USA) 
platform and with FreeSurfer 6.0 (https://surfer.nmr.mgh.harvard.edu/). Baseline and follow-up PET were 
coregistered to baseline T1-weighted magnetic resonance images (MRI) with SPM12. PET and T1-weighted MRI were 
then transformed into standard Montreal Neurological Institute (MNI) stereotactic space using this software. 
Volumes of interest (VOIs) were sampled in MNI space using a modified version of Hammers’ maximum probability 
atlas25. Modifications were similar to those used in the baseline studies; (1) the substantia nigra VOIs were expanded 
and split into lateral and medial halves; (2) a cerebellar reference region was created from the original cerebellar 
VOIs, shrunk by 2 mm and excluding the anterior lobe; (3) for estimation of Braak’s tau stages, entorhinal, precuneus 
and primary visual VOIs were defined; (4) hippocampus and fusiform cortex were split into anterior and posterior 
parts. Cortical VOIs were individualized by convolving the atlas with the subject’s gray matter probability maps 
segmented using an intensity threshold of 0.5. All individualized VOIs and PET coregistrations were visually inspected 
in template space on the normalized T1-weighted MRI. No post-filtering of the PET data was used in the volume of 
interest analyses. All VOI data were extracted in MATLAB using an in-house script. 
For voxel-wise analyses within the substantia nigra, standardized uptake value ratio (SUVR)-maps with intensity 
normalization to the cerebellum reference were created. Difference maps were calculated using SUVR maps of 
baseline and follow-up PET (ΔSUVR = SUVRfollow-up – SUVRbaseline). Using SPM12, voxel-wise two-tailed t-tests of ΔSUVR 
maps of PD-nonMCI and PD-MCI were created with individual groups versus zero, and the one group versus the 
other. Search space was confined to the substantia nigra. Two approaches were used: (1) a conservative approach 
with family-wise error correction (FWE), and a liberal approach with a cluster-defining p-value of 0.01.  
For cortical vertex-wise analysis, T1-weighted MRIs were imported into FreeSurfer using its built-in pipeline. 
Baseline, follow-up and ΔSUVR PET images in MRI space were created using SPM12, and imported into FreeSurfer. A 
6 mm FWHM smooth was applied to increase signal to noise. Using FreeSurfer, a general linear model was created 
including ΔSUVR maps of PD-nonMCI and PD-MCI. Between group t-tests and t-tests versus zero were performed. 
Cluster-wise correction for multiple comparisons was performed using a vertex-wise/cluster-forming threshold p-
value of 0.05, one-sided, positive, to look for signal increase compared to zero. In addition, two models were created 
comparing ΔSUVR in PD patients with (1) ΔMoCA score, one-sided p=0.05, searching for negative correlation, and (2) 
change in UPDRS-III score, one-sided p=0.05, searching for positive correlations. 
Statistical analysis 
Demographics and VOI data were statistical interrogated  with Stata 13.1 (StataCorp LP, Texas). Continuous variables 
were tested for a normal distribution using Shapiro-Wilk’s test, and equality of variance using Bartlett’s test. 
Normally distributed equal variance continuous variables were interrogated using one-way ANOVA, with post hoc 
pairwise comparison of the mean using t-test. Non-normal distributed or unequal variance continuous variables 
were interrogated using the  Kruskall-Wallis test, with post hoc pairwise comparison using Wilcoxon’s (Mann-
Whitney’s) rank-sum test. Because we did not have a healthy control group for follow-up, ΔSUVR values were also 
compared versus zero change using one-sample Student’s t-test or, if non-normally distributed, Wilcoxon’s signed 
rank test. Categorical data were compared using Fisher’s exact test. Linear regression was used for interrogating 
correlations, followed by model verification by diagnostic plots of residuals. The seven VOIs used for Braak staging of 
tau tangle distribution were tested for correlation with changes in MoCA (ΔMoCA = MoCAfollow-up – MoCAbaseline): 
entorhinal, hippocampus, fusiform, middle and inferior temporal gyri, superior temporal gyrus, precuneus and 
primary visual cortex (Supplementary figure 1). P-values <0.05 were considered statistically significant. The Holm 
correction was applied for multiple comparisons in the cortex. 
Results 
All 26 PD patients from baseline were contacted requesting follow-up. Two patients were physically unable to 
attend, two patients had undergone deep brain stimulation surgery, three did not respond.  Two patients were 
excluded due to technical difficulties during scans (delayed start or cerebellum reference outside field of view). 
Demographics and VOI-based analyses at baseline and follow-up for the remaining 17 are presented in the Table. 
Substantia nigra 
The VOI-based analysis revealed no differences between the PD-nonMCI and PD-MCI groups in ΔSUVR of the total 
substantia nigra VOI (N=17, t-test, p=0.22), or in the lateral (p=0.26) or medial subdivisions (p=0.27) (Table 1, Figure 
1). No significant decreases were seen in ΔSUVR in the PD group as a whole (one sample t-test ΔSUVR versus zero, 
N=17, p=0.16), or in the PD-nonMCI alone (N=14, p=0.42). The absence of significant nigral ΔSUVR reductions in the 
PD group as a whole and the PD-nonMCI group was confirmed in the voxel-based analysis (Figure 2). 
A trend towards correlation was seen between change in UPDRS-III score and medial substantia nigra signal (linear 
regression, p=0.08, 95% CI [-34.6 1.9], N=17, all PD patients). There was no significant correlation when looking at 
the total nigra (p=0.28), or restricted to the lateral halves (p=0.82). No correlations were seen between ΔMoCA score 
and ΔSUVR in substantia nigra (N=17; total nigra: p=0.40, 95% CI [-2.8 9.6]; lateral nigra: p=0.39; medial nigra: 
p=0.50). 
Cortex 
The VOI-based analysis revealed no significant group differences in ΔSUVR of any cortical region (Table). We saw two 
non-intuitive trends which did not survive correction for multiple comparisons: (1) decrease in the hippocampus 
SUVR in PD-MCI compared to PD-nonMCI (two sample t-test ΔSUVR, uncorrected p = 0.015, 95% CI of ΔSUVR = [-
0.015 -0.112]), and (2) decreased uptake in the primary visual cortex of PD-nonMCI (one sample t-test ΔSUVR versus 
zero, uncorrected p = 0.026, 95% CI of ΔSUVR = [-0.005 -0.065]).  
Among the pooled PD patients, we found no correlations between ΔMoCA and ΔSUVR in Braak stage defining areas 
(N=17, Pearson correlation, all uncorrected p>0.05).  
The vertex-based analysis revealed no significant clusters after correction for multiple comparisons, when comparing 
flortaucipir ΔSUVR in PD patients against  zero change (Figure 3), or when interrogating for negative correlations 
between ΔSUVR and ΔMoCA, or positive correlations between ΔSUVR and ΔUPDRS-III score.  
Discussion 
We have previously reported on the baseline loss of flortaucipir uptake in the substantia nigra of patients with PD7, 
later reproduced by at least four other groups12,14,16,26. We have also reported the low prevalence and low magnitude 
of tau pathology revealed by flortaucipir PET in PD patients with cognitive deficits pre-dementia 13. These results 
compared well with a similar study by Winer et al.16, and were in line with results including PD patients with 
dementia12,14,15. 
Substantia nigra binding 
In this follow-up study, we did not detect significant loss of flortaucipir signal in the substantia nigra of PD patients at 
two-year follow-up. Fearnley and Lees estimated an exponential 45 % loss of pigmented neurons over the first 10 
years of PD27. With a mean disease duration at baseline of around 4.5 years13, we had expected to see a 9% decrease 
of specific signal over two years. It has been suggested that a proportion of the specific flortaucipir signal may derive 
from MAO-A binding8, though MAO-A concentration appears to remain stable in PD substantia nigra28. We did not 
observe any significant nigral SUVR reduction in the PD group (one sample t-test, ΔSUVR/BaselineSUVR versus zero, 
N=17, p=0.19, 95% CI [-10%; 2%]). It is likely, however, that our study was underpowered to detect a significant loss 
of nigral flortaucipir binding due to the limited sample size and only 2 years of follow-up. Concerning test-retest 
variation of nigral flortaucipir SUVR, Devous et al. reported a standard deviation of mean percent change between 
test and retest of up to 5% using cerebellum as reference29, but this was for much larger VOIs describing entire lobes 
and therefore had better signal to noise ratio. Of interest, we did observe a trend in correlation between worsening 
of motor symptoms and reduction in neuromelanin signal from the medial parts of substantia nigra.  
Cortical binding 
We saw no differences in cortical tau load across either of the PD groups. This is in line with previous studies of 
flortaucipir PET in late stage PD12,14,15. Group-wise differences have been reported, but SUVRs are low compared to 
those seen in AD. Tau tangles are more evident in amyloid positive compared with amyloid negative PD12,14 at pre-
dementia stages16. We did not perform amyloid imaging here due to radiation dose concerns. In the post mortem 
literature, sufficient tau depositions are seen in 30% of end-stage PD patients to allow a secondary diagnosis of AD17. 
It is unclear why flortaucipir PET seems unable to capture this aspect of PD, but possible explanations could be: (1) 
differences in pathologic tau density in earlier PD which may be less evident in PET scans than pathologic staging, 
which rely more on spatial distribution than density37,38; (2) flortaucipir’s preference for neurofibrillary tangles over 
neurites and ghost tangles39, the prevalence of which may be different between PD and AD, and not necessarily 
accounted for during neuropathologic Braak staging; (3) while the microscopically determined tau pathology in both 
diseases is described as neurofibrillary tangles, the phosphorylation fingerprints of AD and PD are different40,  which 
ultimately could affect tracer binding. To our knowledge, only one flortaucipir PET scanned PD case has had post-
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mortem confirmation and this subject was only Braak tau stage 241. As in the baseline study, we observed no 
correlations between MoCA or UPDRS scores and cortical flortaucipir signal at follow-up.  
Possible MAO-B binding 
Since publication of the baseline studies, doubt has emerged towards the specificity of flortaucipir PET. Though 
several targets of flortaucipir were described using autoradiography, including neuromelanin and other iron-binding 
substances5,6, autoradiography has been unable to identify the cause of age-dependent signal increase seen in the 
basal ganglia7,42. The related first generation tau-tracer, THK-5351, was shown to be blocked by MAO-B inhibitor 
selegiline by Ng et al., who demonstrated up to 50% SUV reduction after a single dose of selegiline. This was later 
confirmed  by Villemagne et al. demonstrating up to 82% decrease after five days of selegiline treatment43. The 
crucial aspects of MAO-B binding relates to questions of affinity and distribution. In our original baseline flortaucipir 
data set of PD patients, 59% were treated with MAO-B inhibitors, but these patients did not display lower SUV values 
when compared to the 41% of PD patients, who were not on MAO-B blockers (Thalamus: 95% CI [-11.2%; 24.0%] 
SUV reduction in MAO-B inhibitor treatment group)45. Smith et al. also found no effect of MAO-B inhibitor rasagiline 
on seven PD patients compared to 22 without the medication12. In the present study, one patient had stopped MAO-
B inhibitor treatment nine months prior to follow-up and two patients had stopped, but did not remember exactly 
when, with no seeming effect on SUV (not shown). Rasagiline and selegiline are irreversible MAOB inhibitors and 
their blockade reverses with a half-time of 40 days46,47 as new MAO-B enzymes have to be synthesized.  As a 
consequence, an awareness of the time interval between stopping MAO-B inhibitor treatment and PET could 
become vital. Brain homogenate binding assays by Vermeiren et al., demonstrated  ~75 % blocking of specific 
flortaucipir binding in the thalamus of healthy controls using selegiline. However, the Vermeiren study showed no 
blocking of flortaucipir by selegeline in the temporal lobe of patients with AD, an area known to contain increased 
amounts of MAO-B due to gliosis3,10,47–49. Discrepancies between in vivo and in vitro results have been described 
using other PET tracers50. If the age-dependent increase of flortaucipir signal in the basal ganglia is not caused by 
rising MAO-B, it must be caused by other factors. Choi et al. reported a significant correlation between the signal and 
age-related iron accumulation as estimated by R2* MRI11. This iron may be contained in pigment-like structures, 
known to increase with age51. The amount of MAO-B in PD, recently described by Tong and colleagues28, is no 
different from healthy controls, except for a small increase in the frontal lobe – an area with no reports of increased 
flortaucipir signal in PD, to our knowledge. Consequently, we do not believe MAO-B binding of flortaucipir poses a 
significant problem in our study. 
Possible MAO-A binding 
While flortaucipir’s affinity for MAO-B is rather low, it is higher for MAO-A8. Vermeiren et al. reported blocking 75% 
and 50% of specific activity in the temporal lobes of healthy controls and AD patients, respectively, using the MAO-A 
inhibitor clorgyline. To our knowledge, no similar in vivo blocking study has been performed. The consequences are 
several: (1) SUVR comparisons across groups assume similar MAO-A amounts in the reference and target regions. 
Tong and colleagues reported no difference in MAO-A in substantia nigra and frontal cortex in PD patients compared 
to healthy controls28. They did not report on group differences in the cerebellum28, however, earlier they 
demonstrated a three times larger concentration of MAO-A in healthy control pars compacta of the nigra compared 
to cerebellar cortex52. Consequently, a relative change in “specific signal” does not translate into the same relative 
change in neuromelanin, but underestimates it. (2) Within subject variation over time may affect repeat 
measurements, but MAO-A concentrations are lower and relatively constant, compared to MAO-B52. (3) Though not 
relevant for the present study, it is critical for interpretation of interventional studies that effects demonstrated 
using flortaucipir must also be shown not to come from changes in MAO-A. While this may seem difficult, MAO-A is 
not a marker of gliosis, unlike MAO-B10. Thus, while the differences seen between healthy controls and AD patients 
with THK-5351 PET reflected MAO-B rises due to gliosis, it is unlikely that differences seen with flortaucipir PET 
reflect MAO-A or MAO-B. 
Limitations 
This study has several limitations: (1) The present study lacks a healthy control group with follow-up. Regrettably, 
follow-up scans in healthy controls were refused by our local ethics committee. (2) As with most PET studies, sample 
size is limited due to radiation dosimetry and cost considerations. The PD groups at baseline were of similar size as 
comparable studies, and dropouts cannot be avoided. Future studies with larger sample sizes and longer follow-up 
time are warranted. (3) The specificity of flortaucipir is in question and interpretation may be confounded by MAO-A 
and possibly MAO-B binding though this would be more important if we had seen an increase in cortical uptake. 
MAO-A and MAO-B concentrations in the substantia nigra are probably no different in healthy controls and patients 
with PD28. (4) With follow-up studies, there is a risk of bias in drop-outs. Physical and cognitive decline will increase 
risk of drop-out. This may be the reason why our PD-MCI cohort has lower UPDRS-III score at follow-up – those with 
highest scores at baseline reached levels where they were physically (and possibly cognitively) unable to take part.  
Conclusion 
We saw no significant changes in loss of melanin signal in the substantia nigra or tau load in cortex in PD patients 
using flortaucipir PET at two-year follow-up, and we saw no correlation with changes in cognitive symptoms. Signal 
reduction in the medial substantia nigra trended to correlate with worsening of motor symptoms. Further studies to 
determine the specificity of flortaucipir binding are needed; in particular, in vivo blocking studies of flortaucipir PET 
using MAO-A and MAO-B inhibitors. 
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Table 1 – Demographics and results 
 
  Baseline Follow-up 
 
Controls PD-nonMCI PD-MCI PD-nonMCI PD-MCI 
Subjects, N 23 17 9 14 3 
Age, years 68.6 +/- 7.2 67.6 +/- 6.3 70.5 +/- 7.2  69.5 +/- 6.5 76.2 +/- 7.4  
Sex, male/female 15/8 13/4 9/0 10/4 3/0 
Time to follow-up, years 
   
2.0 +/- 0.2 1.9 +/- 0.3  
MMSE 28.6 +/- 1.3 28.9 +/- 1.3 27.8 +/- 1.5  
  
MoCAB 27.6 +/- 1.4 27.5 +/- 1.7 24.9 +/- 2.8ab 28.3 +/- 1.8 22.0 +/- 2.6 
deltaMoCA C 
   
0.9 +/- 1.7 -2.0 +/- 1.0 b 
UPDRS-IIIB 
 
19.2 +/- 8.4 32.1 +/- 15.4b 25.0 +/- 8.1 29.0 +/- 14.7 
deltaUPDRS 
   
6.1 +/- 7.7 7.3 +/- 3.5  
Substantia nigra total SUVR AC 1.7 +/- 0.2 1.5 +/- 0.2a 1.4 +/- 0.2a 1.5 +/- 0.1 1.2 +/- 0.2b 
Substantia nigra total deltaSUVR  
   
-0.04 +/- 0.17 -0.18 +/- 0.19 
Substantia nigra medial SUVR AC 1.7 +/- 0.2 1.6 +/- 0.3 1.4 +/- 0.2a 1.5 +/- 0.2 1.2 +/- 0.2b 
Substantia nigra medial 
deltaSUVR  
   
-0.04 +/- 0.20 -0.17 +/- 0.14 
Substantia nigra lateral SUVR AC 1.6 +/- 0.2 1.4 +/- 0.2a 1.3 +/- 0.2a 1.4 +/- 0.1 1.1 +/- 0.2b 
Substantia nigra lateral 
deltaSUVR  
   
-0.04 +/- 0.19 -0.19 +/- 0.26 
Entorhinal cortex SUVR  1.1 +/- 0.1 1.0 +/- 0.1 1.1 +/- 0.2 1.0 +/- 0.1 0.9 +/- 0.2 
Entorhinal cortex deltaSUVR  
   
-0.02 +/- 0.07 -0.18 +/- 0.20 
Hippocampus SUVR A 1.1 +/- 0.2 1.0 +/- 0.1a 1.1 +/- 0.2 1.0 +/- 0.1 0.9 +/- 0.2 
Hippocampus deltaSUVR  C 
   
-0.01 +/- 0.08 -0.14 +/- 0.12b 
Fusiform gyrus SUVR  1.2 +/- 0.1 1.1 +/- 0.1 1.1 +/- 0.2 1.1 +/- 0.1 1.1 +/- 0.1 
Fusiform gyrus deltaSUVR  
   
-0.00 +/- 0.07 -0.08 +/- 0.13 
Middle and inferior temporal 
gyrus SUVR  
1.2 +/- 0.1 1.2 +/- 0.1 1.2 +/- 0.1 1.2 +/- 0.1 1.2 +/- 0.1 
Middle and inferior temporal 
gyrus deltaSUVR  
   
0.00 +/- 0.05 -0.04 +/- 0.09 
Superior temporal gyrus SUVR  1.1 +/- 0.1 1.1 +/- 0.1 1.1 +/- 0.1 1.0 +/- 0.1 1.1 +/- 0.1 
Superior temporal gyrus 
deltaSUVR  
   
-0.01 +/- 0.06 -0.01 +/- 0.04 
Precuneus SUVR  1.2 +/- 0.1 1.1 +/- 0.1 1.2 +/- 0.2 1.1 +/- 0.1 1.3 +/- 0.1 
Precuneus deltaSUVR  
   
-0.02 +/- 0.04 0.04 +/- 0.08 
Primary visual cortex SUVR  1.1 +/- 0.1 1.1 +/- 0.1 1.1 +/- 0.1 1.0 +/- 0.1 1.0 +/- 0.1 
Primary visual cortex deltaSUVR  
   
-0.03 +/- 0.05d -0.09 +/- 0.04 
First column: (A/B), groupwise p<0.05 at baseline, ANOVA / Kruskal-Wallis. (C/D), groupwise p<0.05 at follow-up, 
ANOVA / Kruskal-Wallis. Other columns: (a/b): p<0.05, post-hoc t-test or Wilcoxon rank-sum test, versus Controls / 
PD-nonMCI. (d/e): p<0.05, ΔSUVR versus 0, t-test / Wilcoxon signed-rank test). Uncorrected p-values. Mean ± SD.  
Figure 1 
Individual changes in flortaucipir PET SUVR in substantia nigra over time. Left: 95% prediction interval (PI) of controls 
refers to all healthy controls at baseline. Connected symbols represent the same subject, arrow points to follow-up. 
Right: Randomly chosen individual samples. 3mm PET signal smoothing, template space. Lower right color scale 
applies to all images.  
  
 Figure 2 
Voxel-wise analysis within substantia nigra. First row: Mean of all groups at baseline. Second row: Uncorrected p-
values comparing at baseline the groups with healthy controls. Third row: Difference in SUVR when compared to 
healthy controls. Fourth row: Mean change from baseline in those with follow-up. Fifth row: Uncorrected p-values 
when comparing change in SUVR with zero. No voxels survive multiple comparison correction. Neurologic 
orientation, meaning left side of image is left side of patient. Color scales on the right apply to entire row. 
 
  
 
Figure 3 
Vertex-wise cortical analysis. First row: Mean of all groups at baseline. Second row: Mean change from baseline in 
those with follow-up. Red means higher signal at follow-up. Third row: Uncorrected p-values for ΔSUVR > 0. No 
single vertex or cluster of vertices survive multiple comparison correction. Color scales on the right apply to entire 
row. 
 
 
  
Supplementary figure 1.  
Individual changes over time in areas used 
for neuropathologic Braak staging. 
Supplementary figure 2 
Cortical projection images. 6mm smoothing. Same subjects as Figure 1. Color bar shows SUVR, applies to all.  
 
 
